Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239220 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRFOLH1PPARGPPARA | |
| SCHEMBL2101708 | 0.96 | PPARG (0.59) | ALDH1A1TSHRFOLH1PPARGPPARA | |
| SCHEMBL6862461 | 0.91 | NPSR1 (0.54) | ALDH1A1TSHRFOLH1 | |
| SCHEMBL17550410 | 0.91 | NPSR1 (0.54) | ALDH1A1TSHRFOLH1 | |
| SCHEMBL16572101 | 0.89 | ALDH1A1 (0.52) | ALDH1A1TSHRFOLH1PPARGPPARA | |
| SCHEMBL15625987 | 0.88 | CTSK (0.55) | ALDH1A1TSHRPPARGPPARAPPARD | |
| SCHEMBL5970365 | 0.88 | EPHX2 (0.54) | ALDH1A1TSHRFOLH1 | |
| SCHEMBL2628180 | 0.86 | PPARG (0.53) | ALDH1A1TSHRFOLH1PPARGPPARA | |
| SCHEMBL2615858 | 0.86 | PPARG (0.53) | ALDH1A1TSHRFOLH1PPARGPPARA | |
| SCHEMBL6865055 | 0.85 | NPSR1 (0.48) | ALDH1A1TSHRJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | ALDH1A1 99/4885TSHR 4332/4885FOLH1 495/4885 |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | ALDH1A1 99/4885TSHR 4332/4885FOLH1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.